Clinical role of tumour markers in advanced biliary cancers (ABC) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC plus mFOLFOX) in the randomised phase III, multi-centre, open-label ABC-06 trial
Authors
Lamarca, AngelaPalmer, D.
Wasan, H.
Ross, P.
Ma, Y. T.
Arora, A.
Falk, S.
Gillmore, R.
Wadsley, J.
Patel, K.
Anthoney, A.
Maraveyas, A.
Waters, J.
Hoobs, C.
Macdonald, T.
Ryder, D.
Ramage, J.
Davies, L.
Bridgewater, J.
Valle, Juan W
Affiliation
The Christie National Health Service Foundation Trust, Manchester,Issue Date
2022